Is hospitalization still necessary? A systematic review of outpatient HoLEP over the last decade
Abstract
Introduction Holmium laser enucleation of the prostate (HoLEP) is a well-established, size-independent surgical intervention for benign prostatic hyperplasia (BPH). Traditionally performed with overnight hospitalization, there is increasing interest in same-day discharge to reduce healthcare costs and improve patient satisfaction. This systematic review evaluates the feasibility, safety, efficacy, and cost-effectiveness of HoLEP as an outpatient procedure across all patient populations between 2015 and 2025. Material and methods A systematic search of PubMed and Google Scholar was conducted in accordance with PRISMA guidelines, yielding 15 eligible studies including over 1,500 patients. Outcomes analyzed included same-day discharge rates, readmissions, complications, symptom improvement, and patient satisfaction. Subgroup analyses examined outcomes by age, comorbidities, prostate size, and anticoagulation status. Results Same-day discharge (SDD) rates ranged from 60–90%, with contemporary studies achieving rates above 85% in unselected populations. Readmission rates were low (~2–5%), with no significant increase compared to inpatient care. Complication profiles were similar between outpatient and inpatient settings, with most being minor. Functional outcomes such as International Prostate Symptom Score and urinary flow rates showed marked improvement postoperatively, comparable to traditional HoLEP. Advanced laser technology, early surgery scheduling, and standardized…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,500 participants or records.
Read the paper
Related studies
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
- Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
- Long-term outcomes after treatment with Optilume BPH: Four-year results from the EVEREST study
- Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.